Drug Search Results
More Filters [+]

Bleomycin sulfate

Alternative Names: bleomycin sulfate, blenoxane, bleomicina
Latest Update: 2024-07-27
Latest Update Note: Clinical Trial Update

Product Description

A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bleomycin-sulfate)

Mechanisms of Action: DNA Synthesis Inhibition,Protein Synthesis Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Colombia | Dominican Republic | Ecuador | France | Germany | Indonesia | Ireland | Italy | Malaysia | Malta | Mexico | Norway | Pakistan | Peru | Portugal | Russia | Spain | Taiwan | Turkey | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bleomycin sulfate

Countries in Clinic: Belgium, Czech Republic, Denmark, France, Hungary, Italy, Norway, Poland, Spain, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Hodgkin Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

cHOD17

P2

Recruiting

Hodgkin Lymphoma

2027-01-01

C25003

P3

Active, not recruiting

Hodgkin Lymphoma

2026-01-20

HD21 (advanced stage)

P3

Active, not recruiting

Hodgkin Lymphoma

2025-10-18

Recent News Events